Facebook
Twitter
LinkedIn
ForwardPart 2: Importance and Implications of Biomarkers in Diagnosis and Modern Treatment of Alzheimer’s Disease
Not only are cases of mild cognitive impairment (MCI) often not diagnosed, but more than 50% of these patients are misdiagnosed. One contributor to these observations is the fact that with biomarker assessments historically restricted (even in formal guidelines) to research, clinicians commonly rely on clinical scales, often with poor sensitivity to early stages, to generate suspicion of Alzheimer’s disease (AD). With the recent approval of new disease-modifying therapies (DMTs) that must be used within these early windows and their potential impact in the treatment of AD, this suboptimal approach to diagnosis is problematic. This activity will address the importance and available types of biomarker analyses for the diagnosis of AD, and their individual implications for patient selection and application of modern therapeutics.
Target Audience
This activity is intended for neurologists, geriatricians, radiologists, psychiatrists, advanced practice professionals, registered nurses, and pharmacists involved in the diagnosis and management of Alzheimer’s disease.
Learning Objectives
- Define the clinical uses of AD biomarker analyses (e.g., CSF, PET, serum), including both their diagnostic and therapeutic implications, to better streamline and individualize patient management
- Evaluate patient selection for and phase 3 data with new and emerging amyloid-targeting therapies to determine how and for whom their approvals may impact the team-based approach to AD management
. Shepherd, MD, PhD
Credit for this program has expired. The accreditation information below is based on the activity release date.
This activity is jointly provided by Purdue University College of Pharmacy Office of Continuing Education and Professional Development (Purdue) and Efficient LLC.
Designation Statement
Physicians
This enduring activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Efficient, LLC. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University College of Pharmacy designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™.
Nurses
This activity is approved for 0.75 contact hours.
Physician Assistants
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid from 2/28/2023 to 2/27/2024. AAPA reference number: CME-208988.Pharmacists
Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution.
Universal Activity Number (UAN): 0018-9999-23-012-H01-P, .5 contact hours (.05 CEU). Release Date: 02/28/2023 Expiration Date: 02/28/2024
Conflicts of Interest Disclosure Policy:
To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity.
All relevant conflicts of interest have been mitigated prior to the start of the activity.
None of the planners, reviewers, Efficient, LLC staff, and Purdue University College of Pharmacy staff have relevant financial relationship(s) with ineligible companies to disclose unless listed below.
Accredited Provider Disclosures
Faculty Disclosures
Dr. Galvin:
Speakers’ Bureau: Alpha Cognition, Biogen, Cognivue, Eisai, Genentech, Roche
Dr. Shepherd:
Dr. Shepherd has no relevant financial information to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Commercial Supporter
This activity is supported by an educational grant from Genentech, a member of the Roche group.
Available Credit
Price
To access the remainder of the series, click here: https://activities.efficientcme.com/content/AD-Neurobiology